Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

179.20 -0.80 (-0.44%)
Official Closing Price Updated: 7:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
The Smartest Dividend Stocks to Buy With $1,000 Right Now
Via The Motley Fool
Looking Into AbbVie's Recent Short Interest
Via Benzinga
Introducing the "Dividend Seven" Stocks
Via The Motley Fool
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund: 
Via Benzinga
Topics ETFs
Is AbbVie Stock a Buy?
Via The Motley Fool
2 Excellent Dividend Stocks to Buy on the Dip
Via The Motley Fool
Analyst Scoreboard: 19 Ratings For AbbVie
Via Benzinga
Check Out What Whales Are Doing With ABBV
Via Benzinga
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Via The Motley Fool
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Via The Motley Fool
2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond
Via The Motley Fool
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Check Out What Whales Are Doing With ABBV
Via Benzinga
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Via Benzinga
(ABBV) - Analyzing AbbVie's Short Interest
Via Benzinga
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025. 
Via Investor's Business Daily
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth. 
Via The Motley Fool
Neurocrine Wins FDA Approval For Genetic Disorder Drug
The company can launch within a week, says Chief Executive Kyle Gano. 
Via Investor's Business Daily
Exposures Product Safety
1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever
Via The Motley Fool
Topics Stocks
Exposures US Equities
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom improvement and safety. 
Via Benzinga
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges. 
Via Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
Via The Motley Fool
It’s Been A Tough Month For Healthcare Stocks
It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues. 
Via Talk Markets
Topics ETFs Stocks / Equities
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%. 
Via Benzinga
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.